KRAS G12C mutations are strongly associated with tobacco exposure and KRAS G12C-mutant NSCLCs have been consistently reported to have a higher tumor mutational burden (TMB) and a high rate of concurrent mutations such as STK11, KEAP1, SMARCA4 and ATM compared to NSCLCs carrying other KRAS isoforms or KRAS wild-type (WT) (13). This evidence concerns the gene KRAS and neoplasm.